| | |

Machine Learning Could Lead to Earlier Mesothelioma Diagnosis

earlier mesothelioma diagnosis

A machine learning tool being developed by Google could lead to earlier mesothelioma diagnosis and better survival rates.

That word comes from Google artificial intelligence experts who recently presented their research at a developer conference in California.

Machine learning specialist Lily Peng told the gathering that advanced A.I. can detect lung cancers like mesothelioma before doctors can even see them.

Earlier mesothelioma diagnosis would allow for earlier intervention which could mean longer survival for victims of one of the world’s deadliest cancers.

Diagnosis Often Comes Too Late

Mesothelioma is a form of lung cancer caused by asbestos exposure. It can take decades to develop, but It is usually fatal within 18 months of diagnosis.

One reason is that earlier mesothelioma diagnosis is rare. Early pleural mesothelioma is difficult to detect using standard imaging tools. By the time a mesothelioma tumor is large enough to be seen on a CT scan, it may already be very advanced.

Late stage pleural mesothelioma is resistant to most kinds of cancer treatments.

Earlier Mesothelioma Diagnosis with A.I.

Google’s A.I. healthcare team has created a machine learning tool that can recognize very early signs of cancer on imaging scans.

For patients at high risk of mesothelioma or lung cancer, some cancer centers are already using low-dose CT scans to try to spot tumors earlier.

But the Google A.I. takes that system up a notch. The new machine learning tool was “taught” how to spot subtle signs of early lung cancer using scans from the National Cancer Institute and Northwestern University.

Peng offered an example of what the technology can do. She cited the case of a patient who showed no signs of lung cancer on a routine CT scan. A year later, the patient had stage III lung cancer.

Five out of six radiologists could see no signs of cancer on the early scan but the A.I. spotted it. Using the tool for earlier mesothelioma diagnosis has the potential to boost survival rates. Peng estimates it could reduce overall lung cancer deaths by as much as 40 percent.

“Clearly this is a promising but early result,” says Peng. “We are very much looking forward to partnering with the medical community to use technology like this to help improve outcomes for patients.”

Peng and her team will soon publish a paper on the new A.I. in the journal Nature Medicine.

Source:

Murphy, Margi, “Google Says Its A.I. Can Spot Lung Cancer a Year Before Doctors”, May 7, 2019, The Telegraph, https://www.telegraph.co.uk/technology/2019/05/07/google-says-ai-can-spot-lung-cancer-year-doctors/

Google Keynote (Google I/O ‘19), YouTube, https://www.youtube.com/watch?v=TQSaPsKHPqs

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…